Predictions
Elanix Biotechnologies AG
Start price
Target price
Perf. (%)
€0.70
26.11.20
26.11.20
-
26.11.21
26.11.21
-70.00%
27.11.21
27.11.21
Nanorepro AG
Start price
Target price
Perf. (%)
€3.38
26.11.20
26.11.20
-
16.11.21
16.11.21
198.22%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Revenue growth >5% per year expected
Lower EBIT Margin than peer group
Nanorepro AG
Start price
Target price
Perf. (%)
€3.36
16.11.20
16.11.20
-
16.11.21
16.11.21
0.60%
26.11.20
26.11.20
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Revenue growth >5% per year expected
Lower EBIT Margin than peer group
CytoTools AG
Start price
Target price
Perf. (%)
€25.00
15.11.20
15.11.20
-
15.11.21
15.11.21
-66.00%
01.11.21
01.11.21
Probably not worthwhile Investment
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.10
14.11.20
14.11.20
-
14.11.21
14.11.21
-11.71%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Nanorepro AG
Start price
Target price
Perf. (%)
€2.94
11.11.20
11.11.20
-
11.11.21
11.11.21
14.29%
16.11.20
16.11.20
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Revenue growth >5% per year expected
Lower EBIT Margin than peer group
Bio-Gate AG
Start price
Target price
Perf. (%)
€5.90
04.11.20
04.11.20
-
04.11.21
04.11.21
-32.20%
05.11.21
05.11.21
Growths faster than the competition
Few uniques
Dependend from some customers or products
Probably not worthwhile Investment
Nanorepro AG
Start price
Target price
Perf. (%)
€3.50
31.10.20
31.10.20
-
04.11.21
04.11.21
70.29%
20.07.21
20.07.21
Very small cyclical dependencies
Very Future proof/growth oriented business model
Probably not worthwhile Investment
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.90
31.10.20
31.10.20
-
04.11.21
04.11.21
-4.90%
20.07.21
20.07.21
Could be worthwhile Investment >10% per year
Very Future proof/growth oriented business model
Market Leader or Top 3